SEATTLE and SAN FRANCISCO, Feb. 14 /PRNewswire-FirstCall/ --
Researchers from Dendreon Corporation (Nasdaq: DNDN) today presented data
demonstrating the correlation of a measure of the cumulative potency of
PROVENGE (sipuleucel-T), an investigational active cellular immunotherapy
for hormone-refractory prostate cancer, with overall survival. This is the
first time that an association between higher potency of an active immune
therapy and increased patient survival has been reported. The correlation
appeared to be independent of other important baseline prognostic factors.

The abstract (#21), "Cell Number and CD54 Expression in Sipuleucel-T
Correlate with Survival in Metastatic Androgen Independent Prostate
Cancer," is being presented at the American Society of Clinical Oncology's
2008 Genitourinary Symposium in San Francisco.

In two Phase 3 trials, D9901 and D9902A, researchers evaluated
cumulative product release parameters of PROVENGE, including CD54
upregulation (a measure of product potency defined as the increase of CD54
molecules expressed on Antigen Presenting Cells [APC] after incubation with
the PROVENGE Antigen Delivery Cassette(TM)) and the number of total
nucleated cells (TNCs) among patients treated with sipuleucel-T (n=146).
CD54 is a costimulatory molecule which serves as a marker for APCs. Its
expression is increased when APCs become activated and this upregulation of
CD54 serves as a potency release assay for PROVENGE.

Results showed that PROVENGE patients experienced improved survival if
they received more cells across the three doses of PROVENGE (higher
cumulative TNC count (p=0.019)) or higher cumulative CD54 upregulation
values (p=0.009). The effect on survival for TNCs appeared to reflect in
part the patients' baseline prognostic factors. However, the CD54
upregulation ratio appeared to be an independent predictor of survival in
patients who received PROVENGE, as the correlation remained strong even
after adjusting for baseline prognostic factors (p=0.022).

"We have been able to show a correlation between patient survival and a
measure of the cumulative potency of PROVENGE; such a correlation between
product potency and clinical outcome has not been previously demonstrated
with an active immunotherapy," said Mark Frohlich, MD, chief medical
officer of Dendreon. "These data provide further evidence that sipuleucel-T
is actively engaging the immune system in a clinically meaningful way that
prolongs patient survival."

Prostate cancer is the most common non-skin cancer in the United States
and the third most common cancer worldwide. More than one million men in
the United States have prostate cancer, with an estimated 218,890 new cases
expected to be diagnosed in 2007, and more than 27,000 men expected to die
this year from the disease. Currently, there are limited treatment options
for men with advanced, metastatic prostate cancer.

About Active Cellular Immunotherapy with PROVENGE

PROVENGE may represent the first product in a new class of active
cellular immunotherapies (ACIs) that are uniquely designed to use live
human cells to engage the patient's own immune system with the goal of
eliciting a specific long-lasting response against cancer. In clinical
studies, patients typically received three doses of PROVENGE over a
one-month period as a complete course of therapy.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to
target cancer and transform lives through the discovery, development and
commercialization of novel therapeutics that harness the immune system to
fight cancer. The Company applies its expertise in antigen identification,
engineering and cell processing to produce active cellular immunotherapy
product candidates designed to stimulate an immune response. Active
cellular immunotherapy holds promise because it may provide patients with a
meaningful clinical benefit, such as survival, combined with low toxicity.
The Company has its headquarters in Seattle, Washington and is traded on
the NASDAQ Global Market under the symbol DNDN. For more information about
the Company and its programs, visit http://www.dendreon.com.

Except for historical information contained herein, this news release
contains forward-looking statements that are subject to risks and
uncertainties surrounding the efficacy of PROVENGE to treat men suffering
from prostate cancer, risks and uncertainties surrounding the presentation
of data to the FDA and approval of product applications by the FDA and
risks and uncertainties inherent in the process of discovering, developing
and commercializing drugs that are safe and effective for use as human
therapeutics. Factors that may cause such differences include risks related
to our limited operating history, risks associated with completing our
clinical trials, the risk that the safety and/or efficacy results of
existing clinical trials or from additional clinical trials for PROVENGE
will not support approval for a biologics license, the risk that the FDA
may interpret data differently than we do or require more data or a more
rigorous analysis of data than expected, the risk that the FDA will not
approve a product for which a biologics license has been applied, the risk
that the results of a clinical trial for PROVENGE or other product may not
be indicative of results obtained in a later clinical trial, risks that we
may lack the financial resources and access to capital to fund required
clinical trials or commercialization of PROVENGE, our dependence on the
efforts of third parties, and our dependence on intellectual property.
Further information on the factors and risks that could affect Dendreon's
business, financial condition and results of operations are contained in
Dendreon's public disclosure filings with the U.S. Securities and Exchange
Commission, which are available at http://www.sec.gov.

(Date:12/8/2016)... CITY , Dec. 8, 2016 ... US patents for improving the accuracy, reproducibility and ... images in long and small bone orthopaedic applications. ... approach to creating personalized orthopaedic restorations based on ... personalized orthopaedic restorations, the company harnesses the world,s ...

(Date:12/8/2016)... ... 08, 2016 , ... The Dan Carlisle Agency, an Alabama-owned ... is announcing the launch of a charity drive to raise support and awareness ... and children in Birmingham has grown steadily since the 1980’s, and the Pathways ...

(Date:12/8/2016)... Payne, AL (PRWEB) , ... December 08, 2016 ... ... offering insurance and financial consulting services to residential and commercial clients in the ... awareness and support for Nobis Works. , Since 1977, Nobis Works has built ...